


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0701.100E

In Re Application Of: **REDMON et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/082,685	02/25/2002	Russell S. Travers	23405	1617	4621

Title: LACTOSE-FREE, NON-HYGROSCOPIC AND ANHYDROUS PHARMACEUTICAL COMPOSITIONS OF
DESCARBOETHOXYLORATADINE



Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0701.100E

In Re Application: REDMON et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/082,685	02/25/2002	Russell S. Travers	23405	1617	4621

Title: LACTOSE-FREE, NON-HYDROSCOPIC AND ANHYDROUS PHARMACEUTICAL
COMPOSITIONS OF DESCARBOETHOXYLORATADINE



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 08-1935 as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

March 11, 2005

(Date)

Signature of Person Mailing Correspondence

Edward Timmer

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: March 11, 2005

Edward Timmer, Esq.

Attorney for Applicant - Registration No. 46,248

HESLIN ROTHENBERG FARLEY & MESITI P.C.


5 Columbia Circle

Albany, New York 12203

Telephone (518) 452-5600

Faxsimile (518) 452-5579

CC:

INFORMATION DISCLOSURE CITATION <div style="text-align: right; margin-top: -10px;">  </div>	ATTY DOCKET NO. 0701.100E	SERIAL NO. 10/082,685
	APPLICANT(S) REDMON ET AL.	
	FILING DATE 02/25/2002	GROUP 1617

 U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						NO	YES	ABSTRACT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AA	Wirth et al. "Maillard Reaction of Lactose and Fluoxetine Hydrochloride, a Secondary Amine", <i>Journal of Pharmaceutical Sciences</i> , Vol. 87, No. 1, pp. 31-39, January 1998.	
AB	Hodge et al. "The Amadori Rearrangement under New Conditions and its Significance for Nonenzymatic Browning Reactions", <i>J. Am. Chem. Soc.</i> , 1953, Vol. 75, pp. 316-322.	
AC	Kumar et al. "Maillard Reaction and Drug Stability", <i>Maillard Reactions in Chemistry, Food, and Health</i> ; Labunza et al., Eds.; Spec. Pub. 151, Royal Soc. Chem; London, 1994, pp. 20-27.	
AD	Ellis, G.P. "The Maillard Reaction", <i>Adv. Carbohydr. Chem.</i> 1959, Vol. 14, pp. 63-134.	
AE	Yaylayan et al, <i>Critical Reviews in Food and Science Nutrition</i> , 1994, Vol. 34, pp. 321-369.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial here if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	